icon
icon
icon
icon
Upgrade
Upgrade
Current data has a 15-minute delay. Please / to get real-time quotes.
icon
Key StatisticsCurrency:USD
EPS(TTM)
-1.52
P/E(TTM)
-1.41
BVPS
3.06
P/B
0.69
Revenue(2024 Q4)
5.18M
YoY
58.75%
Net Income(2024 Q4)
-34.57M
YoY
0.52%
Gross Margin(TTM)
100.00%
Net Margin(TTM)
-295.96%
ROE(TTM)
-45.58%
Debt ratio
38.22%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy

Profile
C4 Therapeutics, Inc.
A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform
C4 Therapeutics, Inc., was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company dedicated to harnessing the body's natural regulation of protein levels to develop new therapeutic drug candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.
More details
Related Sections
  • Biotechnology+1.37%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
More details
Revenue BreakdownCurrency:USD
Data source:2024 FY
Total
35.58M
Name
Revenue
Proportion
MKDG Agreement
7.30M
20.53%
MERCK Agreement
3.98M
11.18%
Betta Agreements
3.42M
9.60%
Roche Agreement
3.99M
11.21%
Biogen License Agreement
16.90M
47.49%
More details
Major shareholders
Marc A. Cohen;Alain J. Cohen
Perceptive Advisors
Bihua Chen
More details
DividendsCurrency:USD

No Data

Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy

Institutional Holdings
Totally
108
institutions reported their ownerships on
CCCC
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
More details
Stock split and consolidation
Executive Profile
More details
You Can Understand Stocks with AI.
Why NVDA surged 16.40%?
Because it
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App